Fortress Biotech (FBIO) Competitors

Chimerix (NASDAQ:CMRX) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.

Is CMRX or FBIO more profitable?

Chimerix has a net margin of 0.00% compared to Fortress Biotech's net margin of -54.48%. Fortress Biotech's return on equity of 0.00% beat Chimerix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chimerix	N/A	-46.35%	-41.80%
Fortress Biotech	-54.48%	N/A	-28.65%

Does the media prefer CMRX or FBIO?

In the previous week, Chimerix had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for Chimerix and 0 mentions for Fortress Biotech. Chimerix's average media sentiment score of 0.00 beat Fortress Biotech's score of -0.05 indicating that Chimerix is being referred to more favorably in the media.

Company	Overall Sentiment
Chimerix	Neutral
Fortress Biotech	Neutral

Do analysts recommend CMRX or FBIO?

Chimerix presently has a consensus target price of $8.50, indicating a potential upside of 758.59%. Fortress Biotech has a consensus target price of $13.00, indicating a potential upside of 584.21%. Given Chimerix's higher possible upside, equities research analysts clearly believe Chimerix is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chimerix	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer CMRX or FBIO?

Chimerix received 62 more outperform votes than Fortress Biotech when rated by MarketBeat users. However, 63.67% of users gave Fortress Biotech an outperform vote while only 63.50% of users gave Chimerix an outperform vote.

Company	Underperform	Outperform
Chimerix	Outperform Votes 388 63.50%	Underperform Votes 223 36.50%
Fortress Biotech	Outperform Votes 326 63.67%	Underperform Votes 186 36.33%

Which has more risk & volatility, CMRX or FBIO?

Chimerix has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of CMRX or FBIO?

45.4% of Chimerix shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 13.1% of Chimerix shares are held by company insiders. Comparatively, 33.4% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has stronger earnings and valuation, CMRX or FBIO?

Fortress Biotech has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chimerix	$144K	616.27	-$82.10M	-$0.95	-1.04
Fortress Biotech	$84.51M	0.51	-$60.64M	-$3.23	-0.59

Summary

Fortress Biotech beats Chimerix on 10 of the 17 factors compared between the two stocks.